NNC2215, a newly developed glucose-sensitive insulin, auto-adjusts its activity based on blood sugar levels, offering improved glycemic control and reducing the risk of hypoglycemia in diabetes patients. Study: Glucose-sensitive insulin with attenuation of hypoglycaemia . Image Credit: AYO Production/Shutterstock.
com In a recent study published in Nature , researchers report the design and experimental efficacies of NNC2215, a novel insulin conjugate comprising synthetically added glucose-binding macrocycles and glucosides. Unlike conventional insulin interventions, NNC2215 was engineered to demonstrate glucose-concentration-dependent reversible responsive bioactivity. It is capable of preventing insulin overdoses (and the resultant hypoglycemia) but reduces activity at low blood glucose concentrations and increases activity by up to 3.
2 at higher glucose concentrations. The study validated the safety and efficacy of the novel insulin intervention in both in vitro and in vivo systems. Animal model systems revealed that NNC2215’s glucose-sensitive bioactivity was comparable to conventional insulin therapies without the risk of hypoglycemia.
These findings may usher in a new era in diabetes treatment without the need for constant blood glucose monitoring, and insulin dosage comprises the foremost shortcomings of present therapies. Background Diabetes is a common and chronic condition characterized by the body’s inability to maintain glucose homeostasis through intrinsic ins.
